Neuronetics Inc (STIM)
Official siteHEALTHCARE • MEDICAL DEVICES • NASDAQ
Market Cap: $134.10M
Last updated: Nov 17, 2026 at 11:05 AM ET
Neuronetics Inc (STIM) Earnings: Report Dates and Results
Neuronetics (STIM) is expected to report earnings on Mar 15, 2027. In the quarter ended Sep 30, 2026, Neuronetics reported EPS of -$0.02, above the -$0.08 estimate. It beat the EPS estimate in 4 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
STIM has an expected report date of Mar 15, 2027.
STIM Earnings Call
The latest STIM earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 34 quarters below that had an estimate, STIM beat 21, missed 12 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $41.96M, up 12.5% from $37.30M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.02 | -$0.08 | N/A | +75.00% | Beat | N/A | 1 | 2 up, 0 down | Nov 4, 2026 | $41.96M |
| Jun 30, 2026 | -$0.05 | -$0.11 | -$0.13 - -$0.11 | +54.55% | Beat | N/A | 4 | 2 up, 0 down | Aug 11, 2026 | $41.57M |
| Mar 31, 2026 | -$0.15 | -$0.17 | -$0.18 - -$0.17 | +11.76% | Beat | N/A | 3 | 0 up, 2 down | May 5, 2026 | $34.45M |
| Dec 31, 2025 | -$0.10 | -$0.11 | -$0.12 - -$0.10 | +9.09% | Beat | N/A | 2 | 0 up, 1 down | Mar 17, 2026 | $41.78M |
| Sep 30, 2025 | -$0.13 | -$0.12 | -$0.13 - -$0.11 | -8.33% | Miss | N/A | 2 | 0 up, 2 down | Nov 4, 2025 | $37.30M |
| Jun 30, 2025 | -$0.15 | -$0.08 | -$0.08 - -$0.08 | -87.50% | Miss | N/A | 2 | 0 up, 0 down | Aug 5, 2025 | $38.11M |
| Mar 31, 2025 | -$0.21 | -$0.12 | -$0.13 - -$0.11 | -75.00% | Miss | N/A | 3 | 3 up, 0 down | May 6, 2025 | $31.98M |
| Dec 31, 2024 | -$0.33 | -$0.24 | -$0.28 - -$0.23 | -37.50% | Miss | N/A | 4 | 0 up, 0 down | Mar 4, 2025 | $22.49M |
| Sep 30, 2024 | -$0.44 | -$0.23 | -$0.26 - -$0.20 | -91.30% | Miss | N/A | 4 | 0 up, 0 down | Nov 12, 2024 | $18.53M |
| Jun 30, 2024 | -$0.33 | -$0.27 | -$0.27 - -$0.27 | -22.22% | Miss | N/A | 4 | 0 up, 0 down | Aug 12, 2024 | $16.45M |
| Mar 31, 2024 | -$0.27 | -$0.31 | -$0.37 - -$0.26 | +12.90% | Beat | N/A | 4 | 0 up, 0 down | May 7, 2024 | $17.42M |
| Dec 31, 2023 | -$0.19 | -$0.26 | -$0.27 - -$0.25 | +26.92% | Beat | N/A | 4 | 0 up, 0 down | Mar 5, 2024 | $20.31M |
| Sep 30, 2023 | -$0.33 | -$0.28 | -$0.35 - -$0.28 | -17.86% | Miss | N/A | 4 | 0 up, 0 down | Nov 7, 2023 | $17.88M |
| Jun 30, 2023 | -$0.17 | -$0.35 | -$0.36 - -$0.31 | +51.43% | Beat | N/A | 4 | 0 up, 0 down | Aug 8, 2023 | $17.61M |
| Mar 31, 2023 | -$0.38 | -$0.39 | -$0.43 - -$0.35 | +2.56% | Beat | N/A | 4 | 0 up, 0 down | May 9, 2023 | $15.54M |
| Dec 31, 2022 | -$0.30 | -$0.38 | -$0.43 - -$0.30 | +21.05% | Beat | N/A | 4 | 0 up, 0 down | Mar 7, 2023 | $18.20M |
| Sep 30, 2022 | -$0.28 | -$0.42 | -$0.45 - -$0.41 | +33.33% | Beat | N/A | 5 | 0 up, 0 down | Nov 8, 2022 | $16.50M |
| Jun 30, 2022 | -$0.39 | -$0.41 | -$0.44 - -$0.38 | +4.88% | Beat | N/A | 5 | 0 up, 0 down | Aug 2, 2022 | $16.33M |
| Mar 31, 2022 | -$0.41 | -$0.40 | -$0.42 - -$0.37 | -2.50% | Miss | N/A | 5 | 0 up, 0 down | May 12, 2022 | $14.18M |
| Dec 31, 2021 | -$0.29 | -$0.32 | -$0.34 - -$0.29 | +9.38% | Beat | N/A | 5 | N/A | Mar 8, 2022 | $15.02M |
| Sep 30, 2021 | -$0.31 | -$0.30 | -$0.34 - -$0.27 | -3.33% | Miss | N/A | 5 | N/A | Nov 9, 2021 | $13.80M |
| Jun 30, 2021 | -$0.29 | -$0.24 | -$0.25 - -$0.23 | -20.83% | Miss | N/A | 5 | N/A | Aug 3, 2021 | $14.20M |
| Mar 31, 2021 | -$0.31 | -$0.31 | -$0.35 - -$0.27 | 0.00% | In line | N/A | 5 | N/A | May 4, 2021 | $12.29M |
| Dec 31, 2020 | -$0.19 | -$0.24 | -$0.30 - -$0.19 | +20.83% | Beat | N/A | 5 | N/A | Mar 2, 2021 | $15.58M |
| Sep 30, 2020 | -$0.18 | -$0.28 | -$0.32 - -$0.23 | +35.71% | Beat | N/A | 5 | N/A | Nov 2, 2020 | $12.45M |
| Jun 30, 2020 | -$0.41 | -$0.50 | -$0.54 - -$0.48 | +18.00% | Beat | N/A | 4 | N/A | Aug 4, 2020 | $9.74M |
| Mar 31, 2020 | -$0.63 | -$0.46 | -$0.60 - -$0.36 | -36.96% | Miss | N/A | 5 | N/A | May 5, 2020 | $11.48M |
| Dec 31, 2019 | -$0.41 | -$0.44 | -$0.48 - -$0.41 | +6.82% | Beat | N/A | 5 | N/A | Mar 3, 2020 | $17.36M |
| Sep 30, 2019 | -$0.37 | -$0.43 | -$0.46 - -$0.40 | +13.95% | Beat | N/A | 5 | N/A | Nov 5, 2019 | $16.00M |
| Jun 30, 2019 | -$0.39 | -$0.41 | -$0.43 - -$0.35 | +4.88% | Beat | N/A | 5 | N/A | Aug 6, 2019 | $16.57M |
| Mar 31, 2019 | -$0.42 | -$0.40 | -$0.54 - -$0.35 | -5.00% | Miss | -2200.0% | 5 | N/A | May 7, 2019 | $12.73M |
| Dec 31, 2018 | -$0.35 | -$0.37 | -$0.39 - -$0.33 | +5.41% | Beat | N/A | 5 | N/A | Mar 5, 2019 | $15.63M |
| Sep 30, 2018 | -$0.29 | -$0.40 | -$1.47 - -$0.39 | +27.50% | Beat | N/A | 5 | N/A | Nov 6, 2018 | $13.74M |
| Jun 30, 2018 | -$0.67 | -$0.88 | -$1.19 - -$0.39 | +23.86% | Beat | N/A | 5 | N/A | Aug 14, 2018 | $13.25M |
| Mar 31, 2018 | $0.02 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Jun 29, 2018 | $10.15M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$0.59, after -$1.37 the year before. It was -$1.29 for the year ended Dec 31, 2018, the oldest of the 8 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$0.59 | N/A |
| Dec 31, 2024 | -$1.37 | N/A |
| Dec 31, 2023 | -$1.07 | N/A |
| Dec 31, 2022 | -$1.38 | N/A |
| Dec 31, 2021 | -$1.20 | N/A |
| Dec 31, 2020 | -$1.41 | N/A |
| Dec 31, 2019 | -$1.59 | N/A |
| Dec 31, 2018 | -$1.29 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 5,700 words across 8 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 5,665 | 8 | |
| 2026Q2 | Jun 30, 2026 | 5,534 | 7 | |
| 2026Q1 | Mar 31, 2026 | 4,841 | 6 | |
| 2025Q4 | Dec 31, 2025 | 5,850 | 7 | |
| 2025Q3 | Sep 30, 2025 | 5,920 | 7 | |
| 2025Q2 | Jun 30, 2025 | 5,521 | 7 | |
| 2025Q1 | Mar 31, 2025 | 5,237 | 8 | |
| 2024Q3 | Sep 30, 2024 | 3,871 | 7 |
2026Q3 Earnings Call
Opening remarks
Aman Patel ICR Healthcare Representative Good morning, and thank you for joining us for the Neuronetics Third Quarter 2026 Conference Call. Joining me on today's call are Neuronetics' President and Chief Executive Officer, Daniel L. Reuvers, and Chief Financial Officer, Nir Naor. Before we begin, I would like to caution listeners that certain information discussed by management during this conference call will include forward-looking statements related to our business strategy, financial and revenue guidance, and other operational issues and metrics. Actual results can differ materially from the company's expectations. For a discussion of risks and uncertainties associated with Neuronetics' business, I encourage you to review the company's filings with the Securities and Exchange Commission, including the company's annual report on Form 10-K, which was filed in March, and the company's quarterly report on Form 10-Q for the quarter ending March 31, 2026. The company disclaims any obligation to update any forward-looking statement made during the course of this call, except as required by law. During the call, we will also discuss certain information on a non-GAAP basis, including EBITDA. Management believes that non-GAAP financial information, taken in conjunction with U.S. GAAP financial measures, provides useful information for both management and investors by excluding certain noncash and other expenses that are not indicative of trends in our operating results. Reconciliations between U.S. GAAP and non-GAAP results are presented in the tables accompanying our press release, which can be viewed on our website. With that, it is my pleasure to turn the call over to Neuronetics' President and Chief Executive Officer, Daniel L. Reuvers.
Daniel L. Reuvers President and Chief Executive Officer Thanks, Aman, and good morning, everyone. Thank you for joining us for our third quarter 2026 earnings call. I will first walk you through the quarter, reviewing our results on each side of the business, and then I will turn it over to Nir to discuss our financial results in greater detail. I will then come back with how we are thinking about the rest of the year and the setup for 2027 before opening it up for questions. Turning to the quarter, we continued to execute against the profitability and operating cash goals we outlined earlier in the year, and we made meaningful progress on both fronts. Total revenue for the quarter was approximately $42 million, up over 12% versus the third quarter of last year. The results reflect a record quarter for NeuroStar system sales, driven by a welcome reception from customers toward our expanded go-to-market strategy, as well as continued strength within our Greenbrook clinics as we realized ongoing impacts of our revenue cycle management efforts. Diving deeper into our NeuroStar performance, let me start there. Total worldwide revenue was $15.8 million, up approximately 2% year over year.
Frequently Asked Questions About STIM
When is Neuronetics's next earnings date?
Neuronetics's next earnings report is expected for Mar 15, 2027.
Did STIM beat earnings estimates last quarter?
Yes. Neuronetics reported EPS of -$0.02 for the quarter ended Sep 30, 2026, above the -$0.08 estimate, a 75.00% surprise.
What EPS do analysts expect from STIM next quarter?
The consensus EPS estimate for Neuronetics for the quarter ending Dec 31, 2026 is -$0.06 from 6 analysts, with estimates from -$0.07 to -$0.05.
How often does STIM beat earnings estimates?
Neuronetics beat the EPS estimate in 4 of the last 8 quarters, with an average surprise of -7.24%.
STIM pages: Overview, Earnings, Forecast, Financials, Competitors, Government Contracts